Actively Recruiting
Study of IASO208 Injection for Adults Aged 18 to 75 With Relapsed or Refractory B-cell Cancers
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2026-06-01
12
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating IASO208 injection, a gene therapy drug, in adults with relapsed or refractory B-cell malignancies, including various types of lymphoma. This early phase, single-arm, open-label study aims to assess the safety, how the drug moves through the body, and preliminary effectiveness in patients whose disease has returned or not responded to standard treatments. The study uses a dose-escalation design with seven different dose groups ranging from 1E8 TU to 1.8E9 TU. IASO208 is administered as an injection and is a third-generation lentiviral vector gene therapy. Participants receive this treatment in a single arm without comparison groups. Participants will be monitored for up to two years after dosing. Assessments include checking for dose-limiting toxicities within 28 days and adverse events and laboratory abnormalities over two years. Researchers will also measure responses to treatment, survival outcomes, and various blood markers, including viral particle levels and immune cell counts, at multiple time points to evaluate the treatments effects and safety.
CONDITIONS
Brief Title
IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies
Research Team
H
Heng Mei
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here